

# Sedation with Benzodiazepines in MICU

Analysis for Alcalde

*Elizabeth Franco, Jen Cortes*

*March 16, 2016*

## Continuous Data

Shapiro-Wilk normality test is performed and if the data is not normally distributed (the p-value is  $< 0.05$ ), then the Mann-Whitney test is used to compare the medians of the groups.

If the data is normally distributed, an F-test is performed to determine if the groups have equal variances (p-value is  $\geq 0.05$ ) and then the appropriate t-test (with or without equal variances) is used to compare the means of the my.groups.

## Categorical Data

Data is evaluated using the Chi-squared test.

## Results

- age:
  - results:

	BZD	No BZD
<b>n</b>	191	246
<b>nvalid</b>	191	246
<b>mean</b>	56.59	62.99
<b>sd</b>	15.6	17.23
<b>min</b>	19	19
<b>Q1</b>	48	53
<b>median</b>	58	64
<b>Q3</b>	66	74.75
<b>max</b>	94	97
<b>percZero</b>	0	0

- normality:

Table 2: Shapiro-Wilk normality test:  $\mathbf{x}$

Test statistic	P value
0.983	5.319e-05 * * *

- comparison:

Table 3: Wilcoxon rank sum test with continuity correction: `x` by `my.group`

Test statistic	P value	Alternative hypothesis
18067	3.413e-05 * * *	two.sided

- `los`:

- `results`:

	BZD	No BZD
<b>n</b>	191	246
<b>nvalid</b>	191	246
<b>mean</b>	11.38	9.69
<b>sd</b>	8.204	6.109
<b>min</b>	1.46	1.29
<b>Q1</b>	5.4	5.19
<b>median</b>	8.88	7.58
<b>Q3</b>	14.31	13.44
<b>max</b>	53	39.29
<b>percZero</b>	0	0

- `normality`:

Table 5: Shapiro-Wilk normality test: `x`

Test statistic	P value
0.8525	7.88e-20 * * *

- `comparison`:

Table 6: Wilcoxon rank sum test with continuity correction: `x` by `my.group`

Test statistic	P value	Alternative hypothesis
25712	0.09032	two.sided

- `unit.los`:

- `results`:

	BZD	No BZD
<b>n</b>	191	246
<b>nvalid</b>	191	246
<b>mean</b>	5.906	4.906
<b>sd</b>	5.17	3.478
<b>min</b>	1.009	1.187
<b>Q1</b>	2.669	2.696
<b>median</b>	4.018	3.727
<b>Q3</b>	7.423	6.174

	BZD	No BZD
<b>max</b>	34.48	23.44
<b>percZero</b>	0	0

– **normality:**

Table 8: Shapiro-Wilk normality test: **x**

Test statistic	P value
0.7501	3.579e-25 * * *

– **comparison:**

Table 9: Wilcoxon rank sum test with continuity correction: **x** by **my.group**

Test statistic	P value	Alternative hypothesis
25367	0.1525	two.sided

• **vent.duration:**

– **results:**

	BZD	No BZD
<b>n</b>	191	246
<b>nvalid</b>	191	246
<b>mean</b>	99.98	79.45
<b>sd</b>	102.8	70.25
<b>min</b>	24.17	24.25
<b>Q1</b>	40.42	37.07
<b>median</b>	65.08	56.88
<b>Q3</b>	115.8	92.79
<b>max</b>	747.6	566.8
<b>percZero</b>	0	0

– **normality:**

Table 11: Shapiro-Wilk normality test: **x**

Test statistic	P value
0.6667	2.226e-28 * * *

– **comparison:**

Table 12: Wilcoxon rank sum test with continuity correction: **x** by **my.group**

Test statistic	P value	Alternative hypothesis
25852	0.07171	two.sided

Test statistic	P value	Alternative hypothesis
----------------	---------	------------------------

- **weight:**

- **results:**

	BZD	No BZD
<b>n</b>	191	246
<b>nvalid</b>	191	246
<b>mean</b>	90.23	85.02
<b>sd</b>	32.15	32.44
<b>min</b>	36.36	36.36
<b>Q1</b>	68.64	63.73
<b>median</b>	81.82	77.27
<b>Q3</b>	104.8	96.31
<b>max</b>	222.3	238.6
<b>percZero</b>	0	0

- **normality:**

Table 14: Shapiro-Wilk normality test: `x`

Test statistic	P value
0.9005	2.776e-16 * * *

- **comparison:**

Table 15: Wilcoxon rank sum test with continuity correction: `x` by `my.group`

Test statistic	P value	Alternative hypothesis
26453	0.02378 *	two.sided

- **height:**

- **results:**

	BZD	No BZD
<b>n</b>	191	246
<b>nvalid</b>	191	246
<b>mean</b>	169.6	166.7
<b>sd</b>	12.77	17.72
<b>min</b>	121.9	7.62
<b>Q1</b>	162.6	160
<b>median</b>	170.2	167.6
<b>Q3</b>	177.8	175.3
<b>max</b>	256.5	198.1
<b>percZero</b>	0	0

- normality:

Table 17: Shapiro-Wilk normality test: `x`

Test statistic	P value
0.6977	2.871e-27 * * *

- comparison:

Table 18: Wilcoxon rank sum test with continuity correction: `x` by `my.group`

Test statistic	P value	Alternative hypothesis
25407	0.1429	two.sided

- `num.packs.day`:

- results:

	BZD	No BZD
<b>n</b>	191	246
<b>nvalid</b>	91	119
<b>mean</b>	0.2753	0.4781
<b>sd</b>	0.5868	1.907
<b>min</b>	0	0
<b>Q1</b>	0	0
<b>median</b>	0	0
<b>Q3</b>	0.1105	0.375
<b>max</b>	3	20
<b>percZero</b>	73.63	73.11

- normality:

Table 20: Shapiro-Wilk normality test: `x`

Test statistic	P value
0.2297	1.217e-28 * * *

- comparison:

Table 21: Wilcoxon rank sum test with continuity correction: `x` by `my.group`

Test statistic	P value	Alternative hypothesis
5312	0.7646	two.sided

- `num.years.smk`:

- results:

	BZD	No BZD
<b>n</b>	191	246
<b>nvalid</b>	86	107
<b>mean</b>	7.372	6.57
<b>sd</b>	15.62	15.28
<b>min</b>	0	0
<b>Q1</b>	0	0
<b>median</b>	0	0
<b>Q3</b>	0	0
<b>max</b>	61	60
<b>percZero</b>	77.91	81.31

– normality:

Table 23: Shapiro-Wilk normality test: `x`

Test statistic	P value
0.5107	6.681e-23 * * *

– comparison:

Table 24: Wilcoxon rank sum test with continuity correction: `x` by `my.group`

Test statistic	P value	Alternative hypothesis
4746	0.5945	two.sided

• `pack.years`:

– results:

	BZD	No BZD
<b>n</b>	191	246
<b>nvalid</b>	103	119
<b>mean</b>	14.76	11.33
<b>sd</b>	27.96	26.26
<b>min</b>	0	0
<b>Q1</b>	0	0
<b>median</b>	0	0
<b>Q3</b>	25	2.5
<b>max</b>	122	150
<b>percZero</b>	67.96	74.79

– normality:

Table 26: Shapiro-Wilk normality test: `x`

Test statistic	P value
0.5551	1.803e-23 * * *

– **comparison:**

Table 27: Wilcoxon rank sum test with continuity correction: `x` by `my.group`

Test statistic	P value	Alternative hypothesis
6580	0.2342	two.sided

• **sex:**

– **counts:**

	BZD	No BZD
<b>Female</b>	101	134
<b>Male</b>	89	112
<b>Unknown</b>	1	0

– **percents:**

	BZD	No BZD
<b>Female</b>	52.88	54.47
<b>Male</b>	46.6	45.53
<b>Unknown</b>	0.52	0

– **chi.sq:**

Table 30: Pearson's Chi-squared test: `x` and `my.group`

Test statistic	df	P value
1.365	2	0.5053

• **race:**

– **counts:**

	BZD	No BZD
<b>African American</b>	89	96
<b>Asian</b>	2	5
<b>Other</b>	29	42
<b>Unknown</b>	7	17
<b>White/Caucasian</b>	59	80

– **percents:**

	BZD	No BZD
<b>African American</b>	47.85	40
<b>Asian</b>	1.08	2.08
<b>Other</b>	15.59	17.5

	BZD	No BZD
Unknown	3.76	7.08
White/Caucasian	31.72	33.33

– `chi.sq`:

Table 33: Pearson’s Chi-squared test: `x` and `my.group`

Test statistic	df	P value
4.497	4	0.3429

• `disposition`:

– `counts`:

	BZD	No BZD
Acute Care	0	1
Against Medical Advise	2	5
DC/DISC TO REHAB	4	11
DC/TF-Cancer/Childre	1	1
DC/TF TO COURT/LAW	5	1
DC/TF To Psych Hosp	2	5
Deceased	18	37
Discharged to Hospice-Home	1	7
Discharged to Hospice-Medical Facility	8	6
Home	81	84
Home Care with Home Health	37	45
Intermediate Care	5	8
Long Term Care	6	5
Skilled Nursing Facility	21	30

– `percents`:

	BZD	No BZD
Acute Care	0	0.41
Against Medical Advise	1.05	2.03
DC/DISC TO REHAB	2.09	4.47
DC/TF-Cancer/Childre	0.52	0.41
DC/TF TO COURT/LAW	2.62	0.41
DC/TF To Psych Hosp	1.05	2.03
Deceased	9.42	15.04
Discharged to Hospice-Home	0.52	2.85
Discharged to Hospice-Medical Facility	4.19	2.44
Home	42.41	34.15
Home Care with Home Health	19.37	18.29
Intermediate Care	2.62	3.25
Long Term Care	3.14	2.03
Skilled Nursing Facility	10.99	12.2



- **chi.sq:**

Table 36: Pearson’s Chi-squared test: **x** and **my.group**

Test statistic	df	P value
17.41	13	0.1811

- **alt:**

- **counts:**

	BZD	No BZD
<b>FALSE</b>	164	210
<b>TRUE</b>	27	36

- **percents:**

	BZD	No BZD
<b>FALSE</b>	85.86	85.37
<b>TRUE</b>	14.14	14.63

- **chi.sq:**

Table 39: Pearson’s Chi-squared test with Yates’ continuity correction: **x** and **my.group**

Test statistic	df	P value
9.483e-05	1	0.9922

- **ast:**

- **counts:**

	BZD	No BZD
<b>FALSE</b>	142	195
<b>TRUE</b>	49	51

- **percents:**

	BZD	No BZD
<b>FALSE</b>	74.35	79.27
<b>TRUE</b>	25.65	20.73

- **chi.sq:**

Table 42: Pearson's Chi-squared test with Yates' continuity correction: `x` and `my.group`

Test statistic	df	P value
1.211	1	0.2712

- `cam.icu.pos`:

- `counts`:

	BZD	No BZD
<b>FALSE</b>	71	135
<b>TRUE</b>	120	111

- `percents`:

	BZD	No BZD
<b>FALSE</b>	37.17	54.88
<b>TRUE</b>	62.83	45.12

- `chi.sq`:

Table 45: Pearson's Chi-squared test with Yates' continuity correction: `x` and `my.group`

Test statistic	df	P value
12.83	1	0.000342 * * *

- `arf`:

- `counts`:

	BZD	No BZD
<b>FALSE</b>	88	101
<b>TRUE</b>	103	145

- `percents`:

	BZD	No BZD
<b>FALSE</b>	46.07	41.06
<b>TRUE</b>	53.93	58.94

- `chi.sq`:

Table 48: Pearson's Chi-squared test with Yates' continuity correction: `x` and `my.group`

Test statistic	df	P value
0.9074	1	0.3408

- `asthma`:

- `counts`:

	BZD	No BZD
<b>FALSE</b>	178	227
<b>TRUE</b>	13	19

- `percents`:

	BZD	No BZD
<b>FALSE</b>	93.19	92.28
<b>TRUE</b>	6.81	7.72

- `chi.sq`:

Table 51: Pearson's Chi-squared test with Yates' continuity correction: `x` and `my.group`

Test statistic	df	P value
0.03241	1	0.8571

- `ckd`:

- `counts`:

	BZD	No BZD
<b>FALSE</b>	127	168
<b>TRUE</b>	64	78

- `percents`:

	BZD	No BZD
<b>FALSE</b>	66.49	68.29
<b>TRUE</b>	33.51	31.71

- `chi.sq`:

Table 54: Pearson's Chi-squared test with Yates' continuity correction: `x` and `my.group`

Test statistic	df	P value
0.08742	1	0.7675

- `copd`:

- `counts`:

	BZD	No BZD
<b>FALSE</b>	145	171
<b>TRUE</b>	46	75

- `percents`:

	BZD	No BZD
<b>FALSE</b>	75.92	69.51
<b>TRUE</b>	24.08	30.49

- `chi.sq`:

Table 57: Pearson's Chi-squared test with Yates' continuity correction: `x` and `my.group`

Test statistic	df	P value
1.894	1	0.1687

- `dementia`:

- `counts`:

	BZD	No BZD
<b>FALSE</b>	169	212
<b>TRUE</b>	22	34

- `percents`:

	BZD	No BZD
<b>FALSE</b>	88.48	86.18
<b>TRUE</b>	11.52	13.82

- `chi.sq`:

Table 60: Pearson's Chi-squared test with Yates' continuity correction: `x` and `my.group`

Test statistic	df	P value
0.325	1	0.5686

- **diabetes:**

- **counts:**

	BZD	No BZD
<b>FALSE</b>	112	128
<b>TRUE</b>	79	118

- **percents:**

	BZD	No BZD
<b>FALSE</b>	58.64	52.03
<b>TRUE</b>	41.36	47.97

- **chi.sq:**

Table 63: Pearson's Chi-squared test with Yates' continuity correction: `x` and `my.group`

Test statistic	df	P value
1.638	1	0.2006

- **heart.failure:**

- **counts:**

	BZD	No BZD
<b>FALSE</b>	126	159
<b>TRUE</b>	65	87

- **percents:**

	BZD	No BZD
<b>FALSE</b>	65.97	64.63
<b>TRUE</b>	34.03	35.37

- **chi.sq:**

Table 66: Pearson's Chi-squared test with Yates' continuity correction: `x` and `my.group`

Test statistic	df	P value
0.03583	1	0.8499

- **hypertension:**

- **counts:**

	BZD	No BZD
<b>FALSE</b>	53	54
<b>TRUE</b>	138	192

- **percents:**

	BZD	No BZD
<b>FALSE</b>	27.75	21.95
<b>TRUE</b>	72.25	78.05

- **chi.sq:**

Table 69: Pearson's Chi-squared test with Yates' continuity correction: `x` and `my.group`

Test statistic	df	P value
1.653	1	0.1985

- **liver:**

- **counts:**

	BZD	No BZD
<b>FALSE</b>	157	200
<b>TRUE</b>	34	46

- **percents:**

	BZD	No BZD
<b>FALSE</b>	82.2	81.3
<b>TRUE</b>	17.8	18.7

- **chi.sq:**

Table 72: Pearson's Chi-squared test with Yates' continuity correction: `x` and `my.group`

Test statistic	df	P value
0.01349	1	0.9076

- `seizure:`

- `counts:`

	BZD	No BZD
<b>FALSE</b>	156	199
<b>TRUE</b>	35	47

- `percents:`

	BZD	No BZD
<b>FALSE</b>	81.68	80.89
<b>TRUE</b>	18.32	19.11

- `chi.sq:`

Table 75: Pearson's Chi-squared test with Yates' continuity correction: `x` and `my.group`

Test statistic	df	P value
0.007046	1	0.9331

- `diagnosis.categories:`

- `counts:`

	BZD	No BZD
angioedema	8	5
blood glucose	6	15
cardiac	4	9
encephalopathy	4	11
htn	2	6
infection	25	19
other	43	54
renal failure	3	3
respiratory failure	47	70
shock	43	44
w/o	6	10

- `percents:`

	BZD	No BZD
angioedema	4.19	2.03

	BZD	No BZD
<b>blood glucose</b>	3.14	6.1
<b>cardiac</b>	2.09	3.66
<b>encephalopathy</b>	2.09	4.47
<b>htn</b>	1.05	2.44
<b>infection</b>	13.09	7.72
<b>other</b>	22.51	21.95
<b>renal failure</b>	1.57	1.22
<b>respiratory failure</b>	24.61	28.46
<b>shock</b>	22.51	17.89
<b>w/o</b>	3.14	4.07

– **chi.sq:**

Table 78: Pearson’s Chi-squared test: **x** and **my.group**

Test statistic	df	P value
12.62	10	0.246

• **alcohol.use:**

– **counts:**

	BZD	No BZD
<b>FALSE</b>	94	150
<b>TRUE</b>	36	31

– **percents:**

	BZD	No BZD
<b>FALSE</b>	72.31	82.87
<b>TRUE</b>	27.69	17.13

– **chi.sq:**

Table 81: Pearson’s Chi-squared test with Yates’ continuity correction: **x** and **my.group**

Test statistic	df	P value
4.391	1	0.03613 *

• **illicit.drug.use:**

– **counts:**

	BZD	No BZD
<b>FALSE</b>	109	161
<b>TRUE</b>	25	22



– percents:

	BZD	No BZD
<b>FALSE</b>	81.34	87.98
<b>TRUE</b>	18.66	12.02

– chi.sq:

Table 84: Pearson’s Chi-squared test with Yates’ continuity correction: `x` and `my.group`

Test statistic	df	P value
2.197	1	0.1383

• smoking:

– counts:

	BZD	No BZD
<b>current</b>	49	49
<b>none</b>	67	86
<b>past</b>	21	46

– percents:

	BZD	No BZD
<b>current</b>	35.77	27.07
<b>none</b>	48.91	47.51
<b>past</b>	15.33	25.41

– chi.sq:

Table 87: Pearson’s Chi-squared test: `x` and `my.group`

Test statistic	df	P value
5.709	2	0.05758

• benzodiazepines:

– counts:

	BZD	No BZD
<b>FALSE</b>	176	218
<b>TRUE</b>	15	28

– percents:

	BZD	No BZD
<b>FALSE</b>	92.15	88.62
<b>TRUE</b>	7.85	11.38

– **chi.sq:**

Table 90: Pearson’s Chi-squared test with Yates’ continuity correction: `x` and `my.group`

Test statistic	df	P value
1.138	1	0.2862

• **narcotic.analgesics:**

– **counts:**

	BZD	No BZD
<b>FALSE</b>	158	209
<b>TRUE</b>	33	37

– **percents:**

	BZD	No BZD
<b>FALSE</b>	82.72	84.96
<b>TRUE</b>	17.28	15.04

– **chi.sq:**

Table 93: Pearson’s Chi-squared test with Yates’ continuity correction: `x` and `my.group`

Test statistic	df	P value
0.2509	1	0.6164

• **antidepressants:**

– **counts:**

	BZD	No BZD
<b>FALSE</b>	162	203
<b>TRUE</b>	29	43

– **percents:**

	BZD	No BZD
<b>FALSE</b>	84.82	82.52
<b>TRUE</b>	15.18	17.48

- **chi.sq:**

Table 96: Pearson’s Chi-squared test with Yates’ continuity correction: **x** and **my.group**

Test statistic	df	P value
0.2621	1	0.6087

- **antipsychotics:**

- **counts:**

	BZD	No BZD
<b>FALSE</b>	177	223
<b>TRUE</b>	14	23

- **percents:**

	BZD	No BZD
<b>FALSE</b>	92.67	90.65
<b>TRUE</b>	7.33	9.35

- **chi.sq:**

Table 99: Pearson’s Chi-squared test with Yates’ continuity correction: **x** and **my.group**

Test statistic	df	P value
0.3353	1	0.5625

- **anticonvulsants:**

- **counts:**

	BZD	No BZD
<b>FALSE</b>	178	224
<b>TRUE</b>	13	22

- **percents:**

	BZD	No BZD
<b>FALSE</b>	93.19	91.06
<b>TRUE</b>	6.81	8.94

- **chi.sq:**

Table 102: Pearson's Chi-squared test with Yates' continuity correction: `x` and `my.group`

Test statistic	df	P value
0.4079	1	0.5231

- `gamma.aminobutyric.acid.analogs`:

- `counts`:

	BZD	No BZD
<b>FALSE</b>	176	220
<b>TRUE</b>	15	26

- `percents`:

	BZD	No BZD
<b>FALSE</b>	92.15	89.43
<b>TRUE</b>	7.85	10.57

- `chi.sq`:

Table 105: Pearson's Chi-squared test with Yates' continuity correction: `x` and `my.group`

Test statistic	df	P value
0.6406	1	0.4235

## Sedatives

- `dexmedetomidine`:

- `time.wt.avg.rate`:

\* **results** \*:

<code>&amp;nbsp;</code>	BZD	No BZD
<b>n</b>	13	13
<b>nvalid</b>	13	13
<b>mean</b>	0.3503	0.361
<b>sd</b>	0.1748	0.2141
<b>min</b>	0.1	0.1
<b>Q1</b>	0.1823	0.1591

```

**median**    0.4084  0.3715

**Q3**        0.4433  0.531

**max**        0.6572  0.6615

**percZero**   0      0
-----

```

\* **normality**:

```

-----
Test statistic  P value
-----
      0.9191      0.04276 *
-----

```

Table: Shapiro-Wilk normality test: `x`

\* **comparison**:

```

-----
Test statistic  P value  Alternative hypothesis
-----
           80      0.8374      two.sided
-----

```

Table: Wilcoxon rank sum test with continuity correction: `x` by `my.group`

– total.cont.dose:

\* **results**:

```

-----
      &nbsp;      BZD  No BZD
-----
**n**      13    13

**nvalid**  13    13

**mean**    1493  1626

**sd**      1619  2248

**min**     3.409 22.27

**Q1**      202.7 167

**median**  591.1 631.7

**Q3**      2819  2590

**max**     4835  7634

```

```

**percZero**      0      0
-----

```

```

* **normality**:

```

```

-----
Test statistic      P value
-----
      0.7914      0.0001264 * * *
-----

```

Table: Shapiro-Wilk normality test: `x`

```

* **comparison**:

```

```

-----
Test statistic      P value      Alternative hypothesis
-----
      90            0.801            two.sided
-----

```

Table: Wilcoxon rank sum test: `x` by `my.group`

– total.bolus.dose:

```

* **results**:

```

```

-----
      &nbsp;      BZD      No BZD
-----
**n**      13      13
**nvalid**      0      0
**mean**      NA      NA
**sd**      NA      NA
**min**      NA      NA
**Q1**      NA      NA
**median**      NA      NA
**Q3**      NA      NA
**max**      NA      NA
**percZero**      NA      NA
-----

```

```

* **normality**: Insufficient sample size for normality testing

```

```

* **comparison**: Insufficient sample size for inference testing

```

– total.dose:

\* \*\*results\*\*:

&nbsp;	BZD	No BZD
**n**	13	13
**nvalid**	13	13
**mean**	1493	1626
**sd**	1619	2248
**min**	3.409	22.27
**Q1**	202.7	167
**median**	591.1	631.7
**Q3**	2819	2590
**max**	4835	7634
**percZero**	0	0

\* \*\*normality\*\*:

Test statistic	P value
0.7914	0.0001264 * * *

Table: Shapiro-Wilk normality test: `x`

\* \*\*comparison\*\*:

Test statistic	P value	Alternative hypothesis
90	0.801	two.sided

Table: Wilcoxon rank sum test: `x` by `my.group`

- fentanyl:

– time.wt.avg.rate:

\* \*\*results\*\*:

&nbsp;	BZD	No BZD
--------	-----	--------

<b>**n**</b>	257	293
<b>**nvalid**</b>	186	184
<b>**mean**</b>	78.67	67.06
<b>**sd**</b>	47.99	39.33
<b>**min**</b>	12.5	9.768
<b>**Q1**</b>	48.14	38.16
<b>**median**</b>	71.95	58.51
<b>**Q3**</b>	95.07	91.74
<b>**max**</b>	441.5	223.1
<b>**percZero**</b>	0	0

\* **\*\*normality\*\***:

Test statistic	P value
0.858	7.59e-18 * * *

Table: Shapiro-Wilk normality test: `x`

\* **\*\*comparison\*\***:

Test statistic	P value	Alternative hypothesis
19878	0.007186 * *	two.sided

Table: Wilcoxon rank sum test with continuity correction: `x` by `my.group`

– total.cont.dose:

\* **\*\*results\*\***:

&nbsp;	BZD	No BZD
<b>**n**</b>	257	293
<b>**nvalid**</b>	186	184
<b>**mean**</b>	5497	2679
<b>**sd**</b>	7988	3743



<b>**min**</b>	25	22.08
<b>**Q1**</b>	1406	589.6
<b>**median**</b>	2751	1698
<b>**Q3**</b>	6111	3298
<b>**max**</b>	51230	37680
<b>**percZero**</b>	0	0

-----

\* **\*\*normality\*\***:

Test statistic	P value
0.5628	2.221e-29 * * *

-----

Table: Shapiro-Wilk normality test: `x`

\* **\*\*comparison\*\***:

Test statistic	P value	Alternative hypothesis
21869	3.763e-06 * * *	two.sided

-----

Table: Wilcoxon rank sum test with continuity correction: `x` by `my.group`

– total.bolus.dose:

\* **\*\*results\*\***:

&nbsp;	BZD	No BZD
<b>**n**</b>	257	293
<b>**nvalid**</b>	71	109
<b>**mean**</b>	201.1	158.1
<b>**sd**</b>	190.9	152
<b>**min**</b>	2	1
<b>**Q1**</b>	75	50
<b>**median**</b>	125	100

<b>**Q3**</b>	275	200
<b>**max**</b>	1000	875
<b>**percZero**</b>	0	0

\* **\*\*normality\*\***:

Test statistic	P value
0.7863	6.12e-15 * * *

Table: Shapiro-Wilk normality test: `x`

\* **\*\*comparison\*\***:

Test statistic	P value	Alternative hypothesis
4376	0.1367	two.sided

Table: Wilcoxon rank sum test with continuity correction: `x` by `my.group`

– total.dose:

\* **\*\*results\*\***:

&nbsp;	BZD	No BZD
<b>**n**</b>	257	293
<b>**nvalid**</b>	257	293
<b>**mean**</b>	4034	1741
<b>**sd**</b>	7194	3206
<b>**min**</b>	2	1
<b>**Q1**</b>	275	125
<b>**median**</b>	1655	538.5
<b>**Q3**</b>	4156	2290
<b>**max**</b>	51230	37680
<b>**percZero**</b>	0	0

\* \*\*normality\*\*:

Test statistic	P value
0.4987	1.253e-36 * * *

Table: Shapiro-Wilk normality test: `x`

\* \*\*comparison\*\*:

Test statistic	P value	Alternative hypothesis
46962	5.497e-07 * * *	two.sided

Table: Wilcoxon rank sum test with continuity correction: `x` by `my.group`

- hydromorphone:

– time.wt.avg.rate:

\* \*\*results\*\*:

&nbsp;	BZD	No BZD
<b>**n**</b>	16	24
<b>**nvalid**</b>	3	11
<b>**mean**</b>	2.249	0.9427
<b>**sd**</b>	0.8415	0.7443
<b>**min**</b>	1.624	0.09887
<b>**Q1**</b>	1.77	0.4559
<b>**median**</b>	1.917	0.6855
<b>**Q3**</b>	2.561	1.324
<b>**max**</b>	3.206	2.355
<b>**percZero**</b>	0	0

\* \*\*normality\*\*:

Test statistic	P value
----------------	---------

0.932 0.3257

-----  
Table: Shapiro-Wilk normality test: `x`

\* \*\*comparison\*\*:

-----  
Test statistic    P value    Alternative hypothesis  
-----  
29                0.06044            two.sided  
-----

Table: Wilcoxon rank sum test: `x` by `my.group`

– total.cont.dose:

\* \*\*results\*\*:

-----  
&nbsp;                BZD    No BZD  
-----  
\*\*n\*\*            16      24  
  
\*\*nvalid\*\*       3       11  
  
\*\*mean\*\*          207    65.86  
  
\*\*sd\*\*            177.7   96.39  
  
\*\*min\*\*           46      4.309  
  
\*\*Q1\*\*            111.7   10.69  
  
\*\*median\*\*        177.3   31.72  
  
\*\*Q3\*\*            287.5   46.2  
  
\*\*max\*\*           397.6   302.8  
  
\*\*percZero\*\*      0       0  
-----

\* \*\*normality\*\*:

-----  
Test statistic      P value  
-----  
0.7369            0.000915 \* \* \*  
-----

Table: Shapiro-Wilk normality test: `x`

\* \*\*comparison\*\*:

Test statistic	P value	Alternative hypothesis
28	0.08791	two.sided

Table: Wilcoxon rank sum test: `x` by `my.group`

– total.bolus.dose:

\* \*\*results\*\*:

&nbsp;	BZD	No BZD
<b>**n**</b>	16	24
<b>**nvalid**</b>	13	13
<b>**mean**</b>	2.9	4.038
<b>**sd**</b>	3.824	4.611
<b>**min**</b>	0.2	0.2
<b>**Q1**</b>	1	1
<b>**median**</b>	2	2.8
<b>**Q3**</b>	3	5
<b>**max**</b>	15	17
<b>**percZero**</b>	0	0

\* \*\*normality\*\*:

Test statistic	P value
0.6885	3.707e-06 * * *

Table: Shapiro-Wilk normality test: `x`

\* \*\*comparison\*\*:

Test statistic	P value	Alternative hypothesis
70.5	0.4854	two.sided

Table: Wilcoxon rank sum test with continuity correction: `x` by `my.group`

– total.dose:

\* \*\*results\*\*:

	BZD	No BZD
<b>n</b>	16	24
<b>nvalid</b>	16	24
<b>mean</b>	41.16	32.37
<b>sd</b>	104.8	71
<b>min</b>	0.2	0.2
<b>Q1</b>	1.375	2.6
<b>median</b>	2	5.735
<b>Q3</b>	6.75	31.07
<b>max</b>	397.6	302.8
<b>percZero</b>	0	0

\* \*\*normality\*\*:

Test statistic	P value
0.4656	6.846e-11 * * *

Table: Shapiro-Wilk normality test: `x`

\* \*\*comparison\*\*:

Test statistic	P value	Alternative hypothesis
141.5	0.1666	two.sided

Table: Wilcoxon rank sum test with continuity correction: `x` by `my.group`

• ketamine:

– time.wt.avg.rate:

\* \*\*results\*\*:

-----

&nbsp;	BZD	No BZD
-----	-----	-----
<b>**n**</b>	4	8
<b>**nvalid**</b>	2	2
<b>**mean**</b>	0.1178	0.5032
<b>**sd**</b>	0.05404	0.5844
<b>**min**</b>	0.07962	0.08994
<b>**Q1**</b>	0.09872	0.2966
<b>**median**</b>	0.1178	0.5032
<b>**Q3**</b>	0.1369	0.7098
<b>**max**</b>	0.156	0.9164
<b>**percZero**</b>	0	0
-----	-----	-----

\* **\*\*normality\*\***:

Test statistic	P value
-----	-----
0.6969	0.01066 *
-----	-----

Table: Shapiro-Wilk normality test: `x`

\* **\*\*comparison\*\***:

Test statistic	P value	Alternative hypothesis
-----	-----	-----
1	0.6667	two.sided
-----	-----	-----

Table: Wilcoxon rank sum test: `x` by `my.group`

– total.cont.dose:

\* **\*\*results\*\***:

&nbsp;	BZD	No BZD
-----	-----	-----
<b>**n**</b>	4	8
<b>**nvalid**</b>	2	2
<b>**mean**</b>	314.7	718.2

<b>**sd**</b>	190.1	811.6
<b>**min**</b>	180.3	144.3
<b>**Q1**</b>	247.5	431.3
<b>**median**</b>	314.7	718.2
<b>**Q3**</b>	381.9	1005
<b>**max**</b>	449.1	1292
<b>**percZero**</b>	0	0

-----

\* **\*\*normality\*\***:

Test statistic	P value
0.8101	0.1215

-----

Table: Shapiro-Wilk normality test: `x`

\* **\*\*comparison\*\***:

Test statistic	P value	Alternative hypothesis
2	1	two.sided

-----

Table: Wilcoxon rank sum test: `x` by `my.group`

– total.bolus.dose:

\* **\*\*results\*\***:

&nbsp;	BZD	No BZD
<b>**n**</b>	4	8
<b>**nvalid**</b>	3	6
<b>**mean**</b>	97.58	195.8
<b>**sd**</b>	76.39	60.03
<b>**min**</b>	20	100
<b>**Q1**</b>	60	162.5



```

**median**      100    212.5
**Q3**          136.4  243.8
**max**         172.7  250
**percZero**    0      0
-----

```

\* **normality**:

```

-----
Test statistic   P value
-----
      0.9308      0.4885
-----

```

Table: Shapiro-Wilk normality test: `x`

\* **comparison**:

```

-----
Test statistic   P value   Alternative hypothesis
-----
          2.5         0.1182         two.sided
-----

```

Table: Wilcoxon rank sum test with continuity correction: `x` by `my.group`

– total.dose:

\* **results**:

```

-----
      &nbsp;      BZD   No BZD
-----
**n**        4     8
**nvalid**   4     8
**mean**     230.5  326.4
**sd**       163.1  393.9
**min**      100    100
**Q1**       154.5  148.6
**median**   176.5  212.5
**Q3**       252.5  250
**max**      469.1  1292
**percZero** 0     0

```

```
-----
* **normality**:
```

Test statistic	P value
0.5668	5.752e-05 * * *

Table: Shapiro-Wilk normality test: `x`

```
* **comparison**:
```

Test statistic	P value	Alternative hypothesis
13.5	0.7332	two.sided

Table: Wilcoxon rank sum test with continuity correction: `x` by `my.group`

- lorazepam:

- time.wt.avg.rate:

```
* **results**:
```

&nbsp;	BZD	No BZD
<b>**n**</b>	27	42
<b>**nvalid**</b>	2	0
<b>**mean**</b>	1.819	NA
<b>**sd**</b>	0.03969	NA
<b>**min**</b>	1.791	NA
<b>**Q1**</b>	1.805	NA
<b>**median**</b>	1.819	NA
<b>**Q3**</b>	1.833	NA
<b>**max**</b>	1.847	NA
<b>**percZero**</b>	0	NA

```
* **normality**:
```

```
* **comparison**:
```

- total.cont.dose:

\* \*\*results\*\*:

&nbsp;	BZD	No BZD
**n**	27	42
**nvalid**	2	0
**mean**	69.61	NA
**sd**	45.76	NA
**min**	37.25	NA
**Q1**	53.43	NA
**median**	69.61	NA
**Q3**	85.79	NA
**max**	102	NA
**percZero**	0	NA

\* \*\*normality\*\*: Insufficient sample size for normality testing

\* \*\*comparison\*\*: Insufficient sample size for inference testing

– total.bolus.dose:

\* \*\*results\*\*:

&nbsp;	BZD	No BZD
**n**	27	42
**nvalid**	25	42
**mean**	4.18	4.661
**sd**	5.744	9.02
**min**	0.5	0.5
**Q1**	1.5	1
**median**	2	2
**Q3**	4	5
**max**	25	56.5
**percZero**	0	0

```
-----
* **normality**:
```

Test statistic	P value
0.4457	1.731e-14 * * *

Table: Shapiro-Wilk normality test: `x`

```
* **comparison**:
```

Test statistic	P value	Alternative hypothesis
533.5	0.9156	two.sided

Table: Wilcoxon rank sum test with continuity correction: `x` by `my.group`

– total.dose:

```
* **results**:
```

&nbsp;	BZD	No BZD
<b>**n**</b>	27	42
<b>**nvalid**</b>	27	42
<b>**mean**</b>	9.027	4.661
<b>**sd**</b>	20.39	9.02
<b>**min**</b>	0.5	0.5
<b>**Q1**</b>	1.75	1
<b>**median**</b>	2	2
<b>**Q3**</b>	4.5	5
<b>**max**</b>	102	56.5
<b>**percZero**</b>	0	0

```
* **normality**:
```

Test statistic	P value
----------------	---------

```

0.3826      1.653e-15 * * *
-----

```

Table: Shapiro-Wilk normality test: `x`

\* \*\*comparison\*\*:

```

-----
Test statistic   P value   Alternative hypothesis
-----
      616.5      0.5387      two.sided
-----

```

Table: Wilcoxon rank sum test with continuity correction: `x` by `my.group`

- midazolam:

– time.wt.avg.rate:

\* \*\*results\*\*:

```

-----
      &nbsp;      BZD   No BZD
-----
**n**      191   102
**nvalid**  190    0
**mean**    2.456   NA
**sd**      2.148   NA
**min**     0.25    NA
**Q1**      1.143   NA
**median**  1.849   NA
**Q3**      3.108   NA
**max**     15.12   NA
**percZero** 0     NA
-----

```

\* \*\*normality\*\*:

```

-----
Test statistic      P value
-----
      0.7371      4.481e-17 * * *
-----

```

Table: Shapiro-Wilk normality test: `x`

```

* **comparison**: Insufficient sample size for inference testing
- total.cont.dose:

```

```

* **results**:

```

&nbsp;	BZD	No BZD
**n**	191	102
**nvalid**	190	0
**mean**	107.7	NA
**sd**	227.1	NA
**min**	0.008333	NA
**Q1**	10.68	NA
**median**	39.37	NA
**Q3**	115.4	NA
**max**	1939	NA
**percZero**	0	NA

```

* **normality**:

```

Test statistic	P value
0.4457	5.642e-24 * * *

Table: Shapiro-Wilk normality test: `x`

```

* **comparison**: Insufficient sample size for inference testing
- total.bolus.dose:

```

```

* **results**:

```

&nbsp;	BZD	No BZD
**n**	191	102
**nvalid**	77	102
**mean**	7.565	5.392
**sd**	7.902	5.731

<b>**min**</b>	1	1
<b>**Q1**</b>	4	2
<b>**median**</b>	6	4
<b>**Q3**</b>	9	6.375
<b>**max**</b>	56	38
<b>**percZero**</b>	0	0

-----

\* **\*\*normality\*\***:

Test statistic	P value
0.6431	3.528e-19 * * *

-----

Table: Shapiro-Wilk normality test: `x`

\* **\*\*comparison\*\***:

Test statistic	P value	Alternative hypothesis
5036	0.001087 * *	two.sided

-----

Table: Wilcoxon rank sum test with continuity correction: `x` by `my.group`

– total.dose:

\* **\*\*results\*\***:

&nbsp;	BZD	No BZD
<b>**n**</b>	191	102
<b>**nvalid**</b>	191	102
<b>**mean**</b>	110.2	5.392
<b>**sd**</b>	228.2	5.731
<b>**min**</b>	0.008333	1
<b>**Q1**</b>	13.17	2
<b>**median**</b>	41.82	4

```

      **Q3**      117.2    6.375
      **max**      1945     38
      **percZero**    0      0
-----

```

\* **normality**:

```

-----
Test statistic      P value
-----
      0.3767      1.789e-30 * * *
-----

```

Table: Shapiro-Wilk normality test: `x`

\* **comparison**:

```

-----
Test statistic      P value      Alternative hypothesis
-----
      17141      8.351e-27 * * *      two.sided
-----

```

Table: Wilcoxon rank sum test with continuity correction: `x` by `my.group`

- propofol:

– time.wt.avg.rate:

\* **results**:

```

-----
      &nbsp;      BZD    No BZD
-----
      **n**      29     61
      **nvalid**  27     61
      **mean**    26.59  19.89
      **sd**      11.2   13.43
      **min**     7.579   2.5
      **Q1**      17.53  8.611
      **median**  26.3   15.32
      **Q3**      35.93  30.76
      **max**     45.83  56.88
      **percZero**  0     0

```



```

-----

* **normality**:
```

Test statistic	P value
0.9438	0.0008266 * * *

```

-----

Table: Shapiro-Wilk normality test: `x`

* **comparison**:
```

Test statistic	P value	Alternative hypothesis
1112	0.009287 * *	two.sided

```

-----

Table: Wilcoxon rank sum test with continuity correction: `x` by `my.group`

- total.cont.dose:

* **results**:
```

	BZD	No BZD
<b>n</b>	29	61
<b>nvalid</b>	27	61
<b>mean</b>	6154	2851
<b>sd</b>	16926	4675
<b>min</b>	1.8	9.818
<b>Q1</b>	449.5	281.5
<b>median</b>	1451	780
<b>Q3</b>	3609	3336
<b>max</b>	88110	20100
<b>percZero</b>	0	0

```

-----

* **normality**:
```

Test statistic	P value
----------------	---------

0.3445 5.754e-18 \* \* \*

Table: Shapiro-Wilk normality test: `x`

\* \*\*comparison\*\*:

Test statistic	P value	Alternative hypothesis
942	0.2857	two.sided

Table: Wilcoxon rank sum test with continuity correction: `x` by `my.group`

– total.bolus.dose:

\* \*\*results\*\*:

	BZD	No BZD
<b>n</b>	29	61
<b>nvalid</b>	3	0
<b>mean</b>	103.3	NA
<b>sd</b>	95.04	NA
<b>min</b>	10	NA
<b>Q1</b>	55	NA
<b>median</b>	100	NA
<b>Q3</b>	150	NA
<b>max</b>	200	NA
<b>percZero</b>	0	NA

\* \*\*normality\*\*:

Test statistic	P value
0.9991	0.942

Table: Shapiro-Wilk normality test: `x`

\* \*\*comparison\*\*: Insufficient sample size for inference testing

– total.dose:

```
* **results**:
```

&nbsp;	BZD	No BZD
**n**	29	61
**nvalid**	29	61
**mean**	5740	2851
**sd**	16385	4675
**min**	1.8	9.818
**Q1**	352	281.5
**median**	1388	780
**Q3**	3629	3336
**max**	88110	20100
**percZero**	0	0

```
* **normality**:
```

Test statistic	P value
0.3419	3.394e-18 * * *

Table: Shapiro-Wilk normality test: `x`

```
* **comparison**:
```

Test statistic	P value	Alternative hypothesis
950	0.5747	two.sided

Table: Wilcoxon rank sum test with continuity correction: `x` by `my.group`

## References

Data was processed using R version 3.2.4 (2016-03-10) on a x86\_64-w64-mingw32 system.

Prepared by: Brian Gulbis

```
##
```

```
## To cite R in publications use:
```

```

##
## R Core Team (2016). R: A language and environment for
## statistical computing. R Foundation for Statistical Computing,
## Vienna, Austria. URL https://www.R-project.org/.
##
## A BibTeX entry for LaTeX users is
##
## @Manual{,
##   title = {R: A Language and Environment for Statistical Computing},
##   author = {{R Core Team}},
##   organization = {R Foundation for Statistical Computing},
##   address = {Vienna, Austria},
##   year = {2016},
##   url = {https://www.R-project.org/},
## }
##
## We have invested a lot of time and effort in creating R, please
## cite it when using it for data analysis. See also
## 'citation("pkgname")' for citing R packages.

```